• LAST PRICE
    56.3000
  • TODAY'S CHANGE (%)
    Trending Up1.8100 (3.3217%)
  • Bid / Lots
    23.0500/ 1
  • Ask / Lots
    59.9600/ 1
  • Open / Previous Close
    54.4900 / 54.4900
  • Day Range
    Low 52.3700
    High 57.0125
  • 52 Week Range
    Low 14.1900
    High 72.2900
  • Volume
    327,702
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 54.49
TimeVolumeAPGE
09:32 ET373854.075
09:35 ET10052.37
09:39 ET70053.735
09:42 ET740654.145
09:44 ET116853.93
09:46 ET10054.22
09:48 ET65054.49
09:50 ET40054.86
09:51 ET20055.39
09:53 ET10055.32
09:57 ET60053.96
10:00 ET70054.535
10:02 ET10055.06
10:04 ET10054.88
10:06 ET296154.98
10:08 ET10054.92
10:09 ET90054.99
10:11 ET20054.95
10:13 ET40054.9
10:15 ET40054.028
10:18 ET142253.59
10:20 ET53253.79
10:24 ET20053.99
10:26 ET70053.8
10:27 ET97754.25
10:29 ET80353.995
10:36 ET103054.18
10:40 ET60054
10:42 ET83854
10:44 ET80054.305
10:45 ET10054.305
10:49 ET29054.305
10:58 ET472254.038
11:00 ET83554.35
11:05 ET60054.73
11:09 ET20054.735
11:12 ET55154.58
11:18 ET143954.89
11:21 ET10055.015
11:27 ET20055.005
11:36 ET20054.8
11:39 ET40054.66
11:41 ET10054.71
11:45 ET30054.698
11:52 ET20054.69
11:54 ET40054.52
11:56 ET10054.745
12:03 ET20054.68
12:06 ET100554.98
12:10 ET10054.765
12:14 ET20055
12:17 ET10055.29
12:19 ET10055.115
12:24 ET50055.33
12:28 ET10055.5
12:30 ET10055.66
12:32 ET10055.52
12:33 ET10055.52
12:35 ET20055.64
12:37 ET30055.67
12:42 ET30055.9
12:44 ET10055.99
12:48 ET10056.06
12:50 ET10056.02
12:51 ET50055.945
12:53 ET369355.73
12:55 ET10055.67
12:57 ET10055.55
01:00 ET10055.5
01:04 ET40055.605
01:06 ET121455.26
01:08 ET20055.69
01:09 ET30055.55
01:11 ET460555.98
01:13 ET60056.305
01:15 ET32056.005
01:22 ET10056.35
01:24 ET10055.99
01:26 ET10056.31
01:27 ET22055.98
01:33 ET10056.28
01:36 ET22455.985
01:38 ET20056.075
01:40 ET10056.09
01:42 ET10056.11
01:44 ET71756.34
01:45 ET10056.39
01:47 ET30056.39
01:58 ET10056.3
02:00 ET20056.17
02:09 ET73156.29
02:12 ET20056.27
02:16 ET80056.36
02:18 ET18456.31
02:20 ET20056.4
02:21 ET50056.59
02:25 ET10056.62
02:36 ET30056.29
02:38 ET2081256.29
02:39 ET449855.72
02:43 ET171855.715
02:45 ET50055.945
02:48 ET20056
02:52 ET60055.965
02:56 ET20056.13
02:57 ET1340556.32
02:59 ET20056.44
03:01 ET329556.53
03:03 ET50056.73
03:06 ET50056.75
03:08 ET432456.86
03:10 ET10056.875
03:12 ET40056.875
03:14 ET30056.875
03:15 ET469056.74
03:17 ET30056.61
03:19 ET240056.765
03:21 ET167956.95
03:24 ET30056.85
03:26 ET30056.91
03:28 ET30056.89
03:30 ET738056.67
03:32 ET30056.596
03:33 ET50056.48
03:35 ET50056.465
03:37 ET101956.58
03:39 ET70056.47
03:42 ET40056.375
03:44 ET60056.245
03:46 ET445256.09
03:48 ET80056.11
03:50 ET577356.25
03:51 ET220056.26
03:53 ET110056.26
03:55 ET429856
03:57 ET1086855.885
04:00 ET5971256.3
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAPGE
Apogee Therapeutics Inc
3.2B
-25.1x
---
United StatesEWTX
Edgewise Therapeutics Inc
3.2B
-22.5x
---
United StatesXENE
Xenon Pharmaceuticals Inc
3.2B
-15.2x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
United StatesMLTX
MoonLake Immunotherapeutics
3.0B
-51.3x
---
United StatesIOVA
Iovance Biotherapeutics Inc
3.4B
-6.8x
---
As of 2024-11-04

Company Information

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.

Contact Information

Headquarters
221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
Phone
650-394-5230
Fax
302-655-5049

Executives

Independent Chairman of the Board
Mark Mckenna
Chief Executive Officer, Director
Michael Henderson
Chief Financial Officer
Jane Henderson
Chief Medical Officer
Carl Dambkowski
Independent Director
Lisa Bollinger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.2B
Revenue (TTM)
$0.00
Shares Outstanding
58.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.25
Book Value
$7.86
P/E Ratio
-25.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.